Recurrent Endometrial Endometrioid Adenocarcinoma (DBCOND0119273)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05538897	Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers	Ipatasertib Megestrol Megestrol acetate	treatment	1 / 2	recruiting
NCT00492778	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	Chloride ion Cisplatin Platinum	treatment	2	active_not_recruiting
NCT02684227	Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer	Carboplatin Enzalutamide Paclitaxel	treatment	2	completed
NCT03120624	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer	No drug interventions	treatment	1	active_not_recruiting
NCT03348631	Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	No drug interventions	treatment	2	active_not_recruiting
NCT03914612	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer	No drug interventions	treatment	3	active_not_recruiting
NCT03008408	A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma	No drug interventions	treatment	2	active_not_recruiting